Veterans Health Administration Novel Therapeutics Preparedness Act
- Sponsor
- Sen. Sheehy, Tim [R-MT]
- Committees
- Veterans' Affairs Committee (primary)
- Last action
- Apr 29, 2026
Bottom line
The bill aims to proactively prepare the VA healthcare system to safely and effectively integrate novel and emerging mental health treatments, such as psychedelic-assisted therapies, for veterans.
What it actually does
This bill establishes an Office of Novel Therapeutics within the Veterans Health Administration (VHA) to coordinate the evaluation, research, and implementation of emerging therapeutic interventions, particularly for mental health conditions affecting veterans. It mandates the development of national policies, clinical standards, training frameworks, and implementation-readiness plans for these therapies, and creates a Clinical Implementation Program and Centers of Excellence to facilitate their safe and effective integration.
Proponents argue
Proponents argue that emerging therapies, including psychedelic-assisted therapies, hold significant promise for treating conditions like PTSD and depression in veterans, and the VA must be prepared to deliver these treatments safely and consistently. Centralized governance through an Office of Novel Therapeutics will prevent delays, ensure patient safety, and standardize access, leveraging the VA's integrated care model to provide cutting-edge care to those who served.
Opponents contend
Critics might raise concerns about the rapid adoption of therapies still under FDA evaluation, potential safety risks associated with novel treatments, and the significant resource allocation (staff, infrastructure, training) required for intensive therapeutic interventions, especially given existing VA budget constraints and workforce shortages. They might also question the broad scope of "emerging therapeutic interventions" and the potential for premature or unproven treatments to be integrated, diverting resources from established, effective care.
The bill is concise and well-structured, allowing for a quick and comprehensive understanding of its provisions.
Section 1
Short Title
This section establishes the official short name for the Act as the "Veterans Health Administration Novel Therapeutics Preparedness Act." This title provides a concise and recognizable reference for the legislation in public and legislative discourse.
Supporters argue
A clear and concise title helps communicate the bill's purpose and facilitates legislative processes, making it easier for stakeholders to identify and discuss the legislation.
Critics contend
No specific opposition is typically raised against short titles, as they are standard legislative practice.
Tradeoffs
None.
Section 2
Congressional Findings on Emerging Therapies
This section outlines Congress's rationale for the bill, highlighting the potential of emerging therapeutic interventions (like psychedelic-assisted therapies) for veterans' mental health. It notes the unique requirements for administering these therapies, the VA's suitable position for integrated care, and the necessity of centralized planning to avoid delays, ensure safety, and provide consistent access to new treatments.
Section 3(a)(1), new 38 U.S.C. 7392
Establishment of Office of Novel Therapeutics
This provision establishes a new Office of Novel Therapeutics within the Veterans Health Administration, operating under the Office of the Under Secretary for Health. It specifies that the Director of this Office must possess expertise in clinical research and implementation science and will report directly to the Under Secretary for Health, serving as the primary coordinating authority for emerging and novel therapeutic interventions.
Section 3(a)(1), new 38 U.S.C. 7392(d)
Mandated Responsibilities for Novel Therapeutics Integration
This section details 12 specific duties for the new Office, including developing national policy, clinical standards, and a national clinical model for intensive therapeutic interventions. It also mandates implementation-readiness plans (covering facility, team, time allocation, safety protocols), workforce-readiness assessments, training standards, coordination with research, continuity of care guidance, identification of readiness sites, and criteria for Centers of Excellence.
Section 3(a)(1), new 38 U.S.C. 7393
Clinical Implementation Program for Emerging Therapeutics
This section establishes a program to evaluate the effectiveness, feasibility, safety, and scalability of emerging therapeutic interventions within the VA. It specifies using "effectiveness-implementation hybrid models" to gather real-world evidence and assess workforce, infrastructure, cost, and operational requirements. The program can prioritize conditions like PTSD, depression, substance use disorders, and traumatic brain injury, and can be conducted at Centers of Excellence or other medical centers.
Section 3(a)(1), new 38 U.S.C. 7394
Centers of Excellence for Novel Therapeutics
This provision authorizes the Secretary to designate one or more VA medical centers as Centers of Excellence for novel therapeutics. These centers will serve as national leaders in research, clinical training, and implementation, disseminate best practices, provide technical assistance, integrate interdisciplinary care, incorporate veteran advisory input, and coordinate with academic partners. They will operate under standards set by the Office of Novel Therapeutics.
Section 3(a)(1), new 38 U.S.C. 7395
Veteran Advisory Committee on Novel Therapeutics
This section mandates the establishment of a Veteran Advisory Committee on Novel Therapeutics to advise the new Office. Its membership will include veterans with lived experience of VA mental health treatment, veterans who participated in relevant clinical research, family members/caregivers, academic experts, and other subject matter experts. The Committee will provide input on patient safety, informed consent, access barriers, and patient-centered care design.
Section 3(a)(1), new 38 U.S.C. 7396
Mandate for Interagency Coordination
This provision requires the Secretary of Veterans Affairs to coordinate with other federal agencies, including the Department of Health and Human Services, FDA, CMS, Department of Defense, and DEA. The coordination aims to support regulatory readiness, develop reimbursement pathways, address scheduling considerations for controlled substances, and establish shared data infrastructure for monitoring safety, quality, and outcomes related to novel therapeutics.
Section 3(a)(1), new 38 U.S.C. 7397
Annual Reporting on Novel Therapeutics
This section mandates that the Secretary submit an annual report to Congress detailing research activities, clinical outcomes from the Clinical Implementation Program, safety events, workforce readiness, implementation barriers (staffing, procurement, infrastructure), and recommendations for legislative or administrative action related to novel therapeutics.
Section 3(b)
National Preparedness and Implementation Strategy
Within 180 days of enactment, the Secretary must submit a national preparedness and implementation strategy to Congress. This strategy must include detailed workforce capacity assessments, facility modification needs, projected timelines for phased implementation, and identified barriers to implementation for emerging mental health therapeutics across the Veterans Health Administration.
Defines "emerging therapeutic intervention" broadly to include any pharmacological, biological, or other therapeutic modality currently under evaluation or review by the Food and Drug Administration.
New 38 U.S.C. 7391(2)
Why it matters:It is standard legislative practice to define terms upfront to ensure clarity throughout the text. The broadness of this definition is likely intentional to provide flexibility and future-proof the legislation as new therapies emerge.
Case for: This broad definition provides the VA with the necessary flexibility to prepare for a wide range of potential future treatments, not just those currently in public discussion (like psychedelics), ensuring the office remains relevant and adaptable as scientific advancements occur.
Case against: Critics might argue that such a broad definition could allow the VA to dedicate resources to preparing for therapies that are highly speculative or unlikely to receive FDA approval, potentially diverting resources from more certain needs or established treatments.
Estimated impact: Potentially significant, as it dictates the scope of therapies the new office and programs will focus on, influencing future VA healthcare offerings.
Directs the Office of Novel Therapeutics to distinguish between research protocols and clinical implementation standards, ensuring patient care models are not solely constrained by sponsor-driven research design.
New 38 U.S.C. 7392(d)(8)
Why it matters:It is a technical directive within the operational duties of the office, designed to guide how the VA transitions therapies from research to clinical practice. Its placement is logical within the context of the office's functions.
Case for: This provision is crucial for ensuring that once a therapy is approved for clinical use, the VA can adapt its delivery model to best serve veterans' needs, rather than being limited by the often more restrictive parameters of clinical trials designed by pharmaceutical sponsors. This promotes patient-centered care and clinical autonomy.
Case against: No direct opposition, but some might argue that deviating too much from established research protocols could introduce unforeseen variables or risks, especially with novel therapies where long-term effects might still be under investigation.
Estimated impact: Significant for patient access and clinical autonomy within the VA once therapies are approved, potentially allowing for more flexible and individualized treatment approaches.